Novavax To Settle Suit


(MENAFN- Baystreet) Talkspace Hikes on Results

  • Coya Inches up Ahead of ALS Address
  • SolarEdge Stock Suffers Post-Earnings Plunge
  • Pioneer Drops on Newest Numbers
  • Nvidia Wins, Palo Alto Networks Loses, and More Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkin - Thursday, February 22, 2024

    Novavax to Settle Suit

    Novavax (NASDAQ:NVAX) on Thursday said it will settle a bitter arbitration dispute with Gavi, a non-governmental global vaccine organization, over a canceled Covid vaccine purchase agreement.

    Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from the cash-strapped company over the next five years.

    Still, the settlement eliminates what some analysts considered one of the biggest uncertainties around the Covid shot maker, which is cutting costs amid doubts about its ability to remain in business and plummeting demand for Covid products worldwide.

    Shares of Novavax fell more than 50% last year and are down 17% in 2024, putting the company's market value at roughly $470 million.

    In 2022, Novavax terminated a purchase agreement with Geneva-based Gavi. The company cited Gavi's failure to procure the 350 million vaccine doses it agreed to buy in May 2021 on behalf of the COVAX Facility, a global program that aims to distribute Covid vaccines more equitably in lower-income countries.

    Gavi sought a refund for the $700 million it spent on advance payments for Novavax's shots. Novavax has said that those payments were non-refundable.

    Under the settlement, Novavax has paid an initial $75 million to Gavi and will make deferred payments of $80 million each year through Dec. 31. 2028. Those annual payments would be due in quarterly installments.

    NVAX shares boomed $1.41, or 35.4%, to $5.39.





    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

    MENAFN22022024000212011056ID1107888613


  • Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.